SRA880, in vitro characterization of the first non-peptide somatostatin sst(1) receptor antagonist

This report describes the in vitro features of the first somatostatin sst(1) receptor selective non-peptide antagonist, SRA880 ([3R,4aR,10aR]-1,2,3,4,4a,5,10,10a-Octahydro-6-methoxy-1-methyl-benz[g] quinoline-3-carboxylic-acid-4-(4-nitro-phenyl)-piperazine-amide, hydrogen malonate). SRA was evaluate...

Full description

Saved in:
Bibliographic Details
Published in:Neuroscience letters 2004-05, Vol.361 (1-3), p.132-135
Main Authors: Hoyer, D, Nunn, C, Hannon, J, Schoeffter, P, Feuerbach, D, Schuepbach, E, Langenegger, D, Bouhelal, R, Hurth, K, Neumann, P, Troxler, T, Pfaeffli, P
Format: Article
Language:English
Subjects:
Animals
Binding, Competitive - drug effects
Binding, Competitive - physiology
Biological Assay
Cells, Cultured
CHO Cells
Cricetinae
Cyclic AMP - metabolism
Fibroblasts - cytology
Fibroblasts - drug effects
Guanosine 5'-O-(3-Thiotriphosphate) - metabolism
Heterocyclic Compounds, 4 or More Rings - chemistry
Heterocyclic Compounds, 4 or More Rings - pharmacology
Humans
Mice
Molecular Structure
Piperazines - chemistry
Piperazines - pharmacology
Quinolines - chemistry
Quinolines - pharmacology
Radioligand Assay
Rats
Receptors, Neurotransmitter - drug effects
Receptors, Neurotransmitter - metabolism
Receptors, Somatostatin - antagonists & inhibitors
Receptors, Somatostatin - metabolism
Somatostatin - pharmacology
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This report describes the in vitro features of the first somatostatin sst(1) receptor selective non-peptide antagonist, SRA880 ([3R,4aR,10aR]-1,2,3,4,4a,5,10,10a-Octahydro-6-methoxy-1-methyl-benz[g] quinoline-3-carboxylic-acid-4-(4-nitro-phenyl)-piperazine-amide, hydrogen malonate). SRA was evaluated in a number of in vitro systems of various species, both at native and recombinant receptors, using radioligand binding and second messenger/transduction studies. SRA880 has high affinity for native rat, mouse, monkey and human cerebral cortex somatostatin sst(1) receptors (pK(d) = 7.8-8.6) and for human recombinant sst(1) receptors (pK(d) = 8.0-8.1). SRA880 displayed significantly lower affinity for the other human recombinant somatostatin receptors ( pK(d) < or = 6.0) or a wide range of neurotransmitter receptors, except for the human dopamine D4 receptors. SRA880 was characterized in various transduction assays: somatotropin release inhibiting factor (SRIF) induced inhibition of forskolin-stimulated cAMP accumulation, SRIF stimulated-GTPgammaS binding, and SRIF stimulated luciferase gene expression; in all tests, SRA880 was devoid of intrinsic activity and acted as an apparently surmountable antagonist with pK(B) values of 7.5-7.7. Combined with the data from binding studies, these results suggest that SRA880 acts as a competitive antagonist. Thus, SRA880 is the first non-peptide somatostatin sst(1) receptor antagonist to be reported; SRA880 will be a useful tool for the characterization of somatostatin sst(1) receptor-mediated effects both in vitro and in vivo.
ISSN:0304-3940
DOI:10.1016/j.neulet.2004.02.017